10 Affordable Biotech Stocks to Buy Right Now
The article cites BioPharma Dive and PitchBook data showing autoimmune and cancer drug developers received over 40% of venture financing rounds in the first half of 2026, with about $9B invested total and $3.9B in cancer and immune therapies. It then lists 10 U.S.-listed biotech stocks screened for market cap over $2B and forward P/E under 10, including Cogent Biosciences (COGT), which filed an FDA NDA for bezuclastinib and targets initial approvals by end-2026.
How this was made
The 30-second read
Why it matters
For Cogent, the actionable element is the disclosed NDA filing for bezuclastinib and management’s stated engagement with the FDA on multiple submissions, which can drive expectations for regulatory timing and subsequent valuation rerating.
Market read
This is a single-company regulatory milestone within a promotional-style list article, with the main tradable angle being expectations for FDA review progress after the NDA filing.
What to watch
Key swing factors are FDA acceptance, potential requests for additional data, and whether the Phase 3 path for bezuclastinib faces delays beyond management’s end-2026 optimism.
Background
The piece frames 2026 biotech funding trends in immunology and cancer and then spotlights “affordable” US-listed biotech names, using a forward P/E and upside-screening methodology.
Ticker impact
Cogent filed an NDA for bezuclastinib for advanced systemic mastocytosis, citing encouraging APEX key-trial results and FDA engagement.
Moderately positive bias, with upside skew tied to FDA feedback and any subsequent trial or review updates.
The article discloses a specific regulatory step (NDA filing) plus management’s stated optimism on timing, but provides no new efficacy/safety numbers beyond referencing prior trial results.
Market effects
Highlights continued venture funding focus on immunology and cancer, reinforcing the sector narrative for T-cell engager and immune-oncology optionality.
Primarily US regulatory and capital-markets read-through for biotech names with FDA submissions.
Limited, aside from referencing European congress preclinical updates and broader global biotech investor appetite.
Counterpoint
NDA filing does not guarantee approval; without new clinical datapoints or FDA guidance specifics, the market may already price in the regulatory step.
Key entities
- companyCogent Biosciences
Filed a New Drug Application for bezuclastinib for advanced systemic mastocytosis, backed by APEX key-trial results and ongoing FDA engagement.
- drug_candidateBezuclastinib
Selective tyrosine kinase inhibitor targeting KIT receptor mutations in systemic mastocytosis and advanced gastrointestinal stromal tumors.
- clinical_programAPEX key trial
Clinical evidence cited as encouraging support for the NDA filing.
